Despite experiencing mixed results over the past year, the Hopp family remains committed to placing big bets on innovative biotechnologies. In the latest example, the firm provided CureVac GmbH with €80 million to generate Phase IIb survival data for an mRNA cancer vaccine, which it hopes will attract a partner for Phase III testing.

SAP AG co-founder Dietmar Hopp was a business angel to biotech companies for four years before pairing up with advisory firm dievini GmbH in 2005 to form dievini Hopp BioTech Holding GmbH & Co. KG as the Hopp family investment vehicle.